Top Markets
#1 Islamic Coin Islamic Coin +151.30%
#2 Akedo Akedo +77.68%
#3 Glidr Glidr +51.75%
#4 DOVU DOVU +48.65%
#5 Cross Cross +44.14%
#6 Black Phoenix Black Phoenix +33.98%
#7 Velvet Velvet +25.65%
#8 Cap Cap +25.20%
#9 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +18.99%
#10 Palladium Network Palladium Network +12.46%
Coin of the day
Islamic Coin Islamic Coin
Einstellungen
Sprache
DEUTSCH
Währung
USD
Thema
Aceragen, Inc. Aceragen, Inc.

Aceragen, Inc.

ACGN
Rang in Aktien #39037
Aceragen, Inc., a biopharmaceutical firm in its clinical development phase,... Aceragen, Inc., a biopharmaceutical firm in its clinical development phase, operates out of Exton, Pennsylvania, and was founded in 1989. The company, which transitioned from Idera Pharmaceuticals, Inc. and adopted its current name in January 2023, concentrates on the discovery, advancement, and bringing to market of therapeutic agents for uncommon lung and autoimmune conditions exclusively within the United States. Its product development pipeline includes ACG-701, currently undergoing Phase 2 clinical evaluation for both cystic fibrosis pulmonary exacerbations and melioidosis, as well as ACG-801, which is being developed to address Farber disease. Moreover, Aceragen maintains a partnership and option agreement with Scriptr Global, Inc. This collaboration aims to pinpoint, research, and cultivate gene therapy options intended for the management, palliation, diagnosis, or prevention of myotonic dystrophy type 1 and Friedreich's Ataxia.
Aktienkurs
$0.38
Zuletzt synchronisiert: 2023-09-01
Marktkapitalisierung
$677.16K
Veränderung (1 Tag)
0.00%
Veränderung (1 Jahr)
0.00%
Land
US
Handel Aceragen, Inc. (ACGN)

Kategorie

Healthcare
P/B-Verhältnis für Aceragen, Inc. (ACGN)
P/B-Verhältnis zum 2026 TTM: 0
Laut den neuesten Finanzberichten und dem Aktienkurs von Aceragen, Inc. beträgt das aktuelle Kurs-Buchwert-Verhältnis (TTM) 0. Am Ende des Jahres 2026 lag das P/B-Verhältnis bei 0.
P/B-Verlauf für Aceragen, Inc. von 2026 bis 2026
P/B-Verhältnis zum Jahresende
Jahr P/B-Verhältnis ändert
Nicht genügend Daten für die angegebenen Daten.
P/B-Verhältnis für ähnliche Unternehmen oder Wettbewerber
Unternehmen P/B-Verhältnis P/B-Verhältnis-Differenz Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 6.2613 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 6.3483 -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 3.634 -
BE